02.19.15 | 7:07 PMShare 0
Pin 0
Email
The Nasdaq rose for the seventh straight session, driven by biotech stocks. The Composite getting closer to the 5,000 mark. But stocks mostly ended in the red zone amid uncertainty over the prospectsShare 0
Pin 0
Link:
Nasdaq Up for Seventh Straight Session
[…]
Link:
Oncolytics Biotech Completes Enrolment for Reolysin Study – Analyst Blog
[…]
View gallery.Preface: The biotech stocks considered for this review were confined to those over $10 per share that traded at least 500K shares a day based on a 90-day average.For the longest time it seemed that for every new high the S&P 500 hit, biotech stocks, as measured by the iShares Nasdaq Biotechnology Index (NASDAQ: IBB), hit two new […]
Biotech stocks can often make big moves after reporting trial data, but it’s FDA drug approvals or denials that can really make stocks in the industry pop or drop. For that reason, we asked three Motley Fool experts what FDA decisions they’re most excited about. Read on to learn which three companies and drugs are on their radar.Source: Celgene Corporation.: […]
Small-cap biotechnology stocks offer some of the most breathtaking opportunities in the market, but some are better than others. For example, these three tiny biotech stocks are favorites among our Motley Fool experts, and that could mean they’re worth watching.Source: Portola Pharmaceuticals.: Warfarin’s decades long dominance as an anticoagulant used to treat heart disease and post-operative patients is waning, and […]
Source: Gilead Sciences.Gilead Sciences surprised investors when it recently announced that it will begin returning some of its cash stockpile to investors in the form of a dividend. Since dividend-paying biotech stocks are a bit of a rarity, we asked two Motley Fool healthcare experts for their opinion on whether Gilead Sciences’ dividend plan makes sense. Read on to learn […]
Although we don’t believe in timing the market or panicking over market movements, we do like to keep an eye on big changes — just in case they’re material to our investing thesis.The market’s best-performing companies last week included three healthcare stocks that won over investors with can’t-miss news. Two of these companies are highly speculative, emerging-stage biotech stocks that […]
Source: Flickr user Simon & His Camera .Love is in the air, and that makes it the perfect time to confess my affection for three large-cap biotech stocks that market a slate of highly profitable, market-share leading therapies. Read on to learn more about why I have fallen for each of them.No. 1: Celgene CorporationWhile other companies hem and haw […]
Hepatitis C treatment has progressed by leaps and bounds in the past few years, and appears to be accelerating even more quickly now. Cure rates have increased, treatment times are plummeting, and side effects are falling away. Is now the time to jump into the biotechs researching new drugs?Industry Focus takes a look at Regulus Therapeutics and Achillion Pharmaceuticals […]
View photo.Biotech stocks have performed well in the recent bull market.Since January 1, 2008, the SPDR S&P Biotech ETF (NYSE: XBI) has outperformed the SPDR S&P 500 ETF Trust (NYSE: SPY), gaining 233 percent compared with just 41.3 percent gains in SPY.Analysts at Sterne Agee took a closer look at three active biotech companies in separate notes Friday morning.Molina Healthcare, […]
